Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab vs Pembrolizumab in Metastatic Non-Squamous NSCLC
NCT04581824Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
A Phase 2 trial of dostarlimab in non-squamous non-small cell lung cancer, sponsored by GSK. Started Nov 2020; status: terminated.
02
Drugs
dostarlimab
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on NCT04581824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581824.